Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate CAS 328086-60-8 PF-07321332 Boceprevir Intermediate

Short Description:

Chemical Name: Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate 

CAS: 328086-60-8

Appearance: White to Off-White Powder

Intermediate of PF-07321332 Paxlovid (CAS 2628280-40-8) and Boceprevir (CAS 394730-60-0)

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401


Product Detail

Related Products

Product Tags


328086-60-8 - Chemical Properties:

Chemical Name Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate
Synonyms Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopyrrolidin-3-yl)propanoate; (αS,3S)-α-[(tert-Butyloxycarbonyl)aMino]-2-oxo-3-pyrrolidinepropanoic acid Methyl Ester; (S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopyrrolidin-3-yl)propanoate
CAS Number 328086-60-8
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C13H22N2O5
Molecular Weight 286.33
Density 1.142±0.06 g/cm3
COA & MSDS Available
Origin of Product    Shanghai, China
Product Categories Pharmaceutical Intermediates
Brand Ruifu Chemical

328086-60-8 - Specifications:

Item Specifications
Appearance White to Off-White Powder
Identification A IR: Similar to Reference Substance
Identification B Retention Time: Similar to Reference Substance
Loss on Drying ≤1.00%
Residue on Ignition ≤0.20%
Total Impurities ≤2.00%
Purity ≥98.0% 
Infrared Spectrum Conforms to Structure
NMR Spectrum Conforms to Structure
Test Standard Enterprise Standard
Usage: Intermediate of PF-07321332 Paxlovid (CAS 2628280-40-8) and Boceprevir (CAS 394730-60-0)

328086-60-8 - Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture 



328086-60-8 - FAQ:

328086-60-8 - Application:

Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate (CAS 328086-60-8) is the intermediate of PF-07321332 Paxlovid (CAS 2628280-40-8) and Boceprevir (CAS 394730-60-0). PF-07321332, the key component of Paxlovid (PF-07321332 and Ritonavir) which is an investigational COVID-19 oral antiviral candidate, is an orally bioavailable 3C-like protease (3CLPRO) inhibitor with potent antiviral effects against SARS-CoV-2 virus and COVID-19. On Nove 6th 2021, Pfizer announced that Paxlovid significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. Boceprevir (EBP-520) is an HCV protease inhibitor (Ki=14 nM) for the treatment of hepatitis C virus infection. Boceprevir with pegylated interferon and ribavirin (PegIFN/RBV) enabled improvement in sustained virological response rates of patients with genotype 1 HCV. Boceprevir interacts with immunosuppressive therapy (IT) by inhibiting the cytochrome P450 3A enzyme.

  • Write your message here and send it to us